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Abstract
Background: Non-Hodgkin lymphoma (NHL) is a hematologic malignancy for which good diagnostic markers are
lacking. Despite continued improvement in our understanding of NHL, efforts to identify diagnostic markers have
yielded dismal results. Here, we translated low-mass-ion information in urine samples from patients with NHL into
a diagnostic marker.
Methods: To minimize experimental error, we tested variable parameters before MALDI-TOF analysis of low-mass
ions in urine. Urine from 30 controls and 30 NHL patients was analyzed as a training set for NHL prediction. All
individual peak areas were normalized to total area up to 1000 m/z. The training set analysis was repeated four
times. Low-mass peaks that were not affected by changes in experimental conditions were collected using
MarkerView™ software. Human Metabolome Database (HMDB) searches and ESI LC-MS/MS analyses were used to
identify low-mass ions that exhibited differential patterns in control and NHL urines. Identified low-mass ions were
validated in a blinded fashion in 95 controls and 66 NHL urines to determine their ability to discriminate NHL
patients from controls.
Results: The 30 highest-ranking low-mass-ion peaks were selected from the 60-urine training set, and three low-
mass-ion peaks with high intensity were selected for identification. Of these, a 137.08-m/z ion showed lower mass-
peak intensity in urines of NHL patients, a result that was validated in a 161-urine blind validation set (95 controls
and 66 NHL urines). The 130.08-m/z ion was identified from HMDB searches and ESI LC-MS/MS analyses as
hypoxanthine (HX). The HX concentration in urines of NHL patients was significantly decreased (P < 0.001) and was
correlated with the mass-peak area of the 137.08-m/z ion. At an HX concentration cutoff of 17.4 μM, sensitivity and
specificity were 79.2% and 78.4%, respectively.
Conclusions: The present study represents a good example of low-mass-ion profiling in the setting of disease
screening using urine. This technique can be a powerful non-invasive diagnostic tool with high sensitivity and
specificity for NHL screening. Furthermore, HX identified in the study may be a useful single urine marker for NHL
screening.
Backgrounds
Non-Hodgkin lymphomas (NHL) are a heterogeneous
group of malignancies that arise from lymphoid tissue.
They exhibit varied clinical and biological features [1],
and their incidence has been increasing over the past
several decades [2]. The past decade has seen enormous
changes in our understanding of lymphomas, including
the identification of better prognostic factors [3]. How-
ever, results from efforts to identify good diagnostic fac-
tors have been disappointing. Lactate dehydrogenase has
been used as an NHL marker [4], but its accuracy in
diagnosis has been unsatisfactory. Thus, finding specific
tumor markers that are useful for diagnosing and moni-
toring NHL remains a high priority. In the present
study, we introduce a new NHL diagnostic marker
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(i.e., < 1000 m/z) in urine samples from lymphoma
patients.
Methods
Urine from patients with NHL
Urine samples were obtained from 125 healthy controls
(65 males and 60 females, median age 50.0 years old)
and 96 patients with NHL (61 males and 35 females,
median age 57.0 years old). All samples were stored at
4°C before processing and were processed within 6
hours of collection. Processed samples were frozen at
-80°C until assessment. The characteristics of NHL
patients are listed in Table 1. Informed consent was
obtained from all patients, and the research protocol
was approved by the Institutional Review Board of the
National Cancer Center, Korea (NCCCTS-05-146).
MALDI-TOF analytical conditions for collecting low-mass
ions in urine
Urine samples were mixed (1:12) with an a-cyano-4-
hydroxycinnamic acid solution in 50% acetonitrile/0.1%
trifluoroacetic acid (TFA). Differences between normal
and cancer urine samples were determined using a 4700
Proteomic Analyzer (Applied Biosystems, Foster City,
CA, USA). The mass-spectral data represent the average
of 20 accumulated spectra.
Low-mass ion selection and statistical analysis
All MALDI mass spectra, formatted as *.t2d files, were
analyzed with MarkerView™ Software version 1.2
(Applied Biosystems/MDS Sciex, Toronto, Canada). The
optimized parameters used to compare low-mass peaks
in urines from controls and NHL patients were as fol-
low: Mass tolerance, 100 ppm; minimum required
response, 100; maximum number of peaks, 5000; nor-
malization, by total area sums. After collecting informa-
tion from MALDI mass spectra, principal component
analyses (PCA) and t-tests were used to select low-mass
ions with differential peak intensities in urines from
controls and NHL patients.
ESI-MS/MS for low-mass ion analysis
MALDI-TOF was not suitable for comparing MS/MS
p a t t e r n so fl o w - m a s si o n s ,s oE S I - M S / M Sw a s
employed. The mass spectrometer was set for ESI in
positive mode. A syringe pump was used to introduce
the calibration solution for automatic tuning and cali-
bration of the LTQ-XL (Thermo Fisher Scientific Inc.,
Waltham, MA) in ESI positive-ion mode. Standard solu-
tions (1 μM hypoxanthine) were infused directly into
the ionization source of the mass spectrometer using a
syringe pump (1.0 μL/min) without chromatographic
separation. The spray voltage was set at +1.1 kV; the
temperature of the capillary was set at 200°C; the capil-
lary voltage was set at +20 V; the tube lens voltage was
set at +100 V; and the auxiliary gas was set to zero.
Full-scan experiments were performed to linear trap in
the range, 100-200 m/z. Systematic MS/MS experiments
were performed by changing the relative collisional
energy and monitoring the intensities of the fragment
ions. MS/MS data were acquired from urine samples.
Table 1 The characteristics of 96 NHL patients
No. of Patients (%)
Age, years (median, range) 57, 23-87
Sex
Male 61 (63.5)
Female 35 (36.5)
Histologic type (WHO)
Diffuse large B cell lymphoma 70 (72.9)
Mantle cell lymphoma 6 (6.2)
T cell lineage 16 (16.7)
Follicular lymphoma 2 (2.1)
Burkitt’s lymphoma 2 (2.1)
Performance status
0 32 (33.3)
1 60 (62.5)
2 4 (4.2)
Stage
I 16 (16.7)
II 40 (41.6)
III 18 (18.8)
IV 22 (22.9)
Extra-nodal involvement
Absent 43 (44.8)
Present 57 (55.2)
IPI
Low 52 (54.1)
Low-intermediate 18 (18.8)
High-intermediate 20 (20.8)
High 6 (6.3)
Bone marrow involvement
Absent 90 (93.8)
Present 5 (5.2)
Not identified 1 (1.0)
Therapeutic regimen
R-CHOP 79 (82.3)
CHOP 8 (8.3)
Others 9 (9.4)
In histologic type, T cell lineage includes anaplastic large cell lymphoma,
angioimmunoblastic T cell lymphoma, peripheral T cell lymphoma, and NK/T
cell lymphoma. Except of follicular lymphoma as an indolent type of NHL, all
other histologic subclasses represent aggressive type.
Performance status was determined according to the criteria, ECOG score.
IPI: international prognostic index
CHOP regimen includes cyclophosphamide, doxorubicin, vincristine, and
prednisolone. R-CHOP is a combination regimen of CHOP with the anti-CD20
monoclonal antibody, rituximab.
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Page 2 of 9Dtermination of hypoxanthine and xanthine in urines
The concentration of hypoxanthine and xanthine in urines
was determined using the Amplex® Red Xanthine/
Xanthine Oxidase Assay Kit (Molecular Probes, Inc.,
Eugene, OR), according to the manufacturer’s instructions.
Results
Experimental conditions for MALDI MS analysis of low-
mass ions in urine
To minimize experimental error, we tested variable para-
meters, including focus mass, laser intensity, target plate
and data-acquisition time. Ideal focus mass and laser
intensity for analyzing low-mass ions (< ~1000 m/z) were
fixed at 500 m/z and 5250, respectively (Figure 1A, B and
1C). Using these focus mass and laser intensity settings,
we analyzed one urine sample four times under different
target and data acquisition times. Low-mass peaks that
were not significantly affected by experimental conditions
were selected and subsequently evaluated for their poten-
tial ability to discriminate NHL from normal controls
(Figure 1D).
Selection of low-mass ions differentially present in
control and NHL urines
Using MarkerView™ statistical software, we compared the
patterns of low-mass ion spectra in urines of 30 normal
and 30 NHL patients. Contamination by the chemical
matrix used in MALDI-TOF analysis was ruled out based
on a statistical analysis (data not shown). A principal
component analysis (PCA) showed differential peak pat-
terns of low-mass ions in control and NHL urines (Figure
2A). Among the low-mass ions ranked in the top 30 by
PCA (Figure 2B), three with the highest peak intensity
were selected for further analysis. The peak intensity of
the 137.08-m/z ion was much lower in urines from NHL
patients than in normal urines (P < 0.001) (Figure 2B
&2C), whereas those of the other two selected low-mass
ions (172.07 and 182.07 m/z) were higher in urines from
NHL patients (both P < 0.001) (Figure 2B). A profile plot
of 137.08-m/z peaks suggested that this ion has discrimi-
nating power for NHL screening (Figure 2C).
Identifications for the 137.1 m/z ion in urine as
hypoxanthine
Candidate metabolites corresponding to the 137.08-m/z
ion were searched using the Human Metabolome Data-
base (HMDB). Many metabolites with a mass tolerance
of 137.08 ± 0.05 (137.08 m/z was rounded off to three
decimal places) were searched in positive mode. Among
these, only eight appeared as an M+H adduct (Table 2).
Because it is a representative metabolite in urine meta-
bolic pathways, Hypoxanthine was tested first to deter-
mine whether it corresponded to the 137.08 m/z mass
peak in urine. To assure the best possible MS/MS
analysis of low-mass ions, we employed ESI LC-MS/MS
(LTQ-XL, Thermo Fisher Scientific Inc., Waltham, MA),
monitoring the mass-shift of hypoxanthine and the
137.08-m/z ion in urine at 137.70 m/z (Figure 3A). Inter-
estingly, the MS/MS pattern of both low-mass ions was
identical (Figure 3B). In contrast, the MS/MS patterns of
other candidate metabolites, such as N-methylnicotina-
mide (Table 2), differed from that of the 137.1-m/z ion in
urine (data not shown), and were thus ruled out.
The mass-peak area of the 137.08-m/z ion and hypox-
anthine were correlated with one another (Figure 3C),
but this relationship did not reach statistical signifi-
cance. Mass accuracy (Figure 3A &3B) and the relation-
ship between mass-peak area of the 137.08-m/z ion and
hypoxanthine concentration (Figure 3C) suggested that
differential levels of HX in control and NHL urines
resulted in a change in the mass-peak area of the
137.08-m/z ion. Despite this unsatisfied statistical rela-
tionship, hypoxanthine was significantly reduced in
NHL urines (P < 0.001); at a 17.4-μM cutoff, specificity
and sensitivity were 78.4% and 79.2%, respectively (Fig-
ure 4A). Furthermore, xanthine produced from hypox-
a n t h i n eb yx a n t h i n eo x i d a s ew a sa l s ol o w e ri nN H L
urines, and showed a similar NHL-discriminating power
(76.0% specificity and 78.1% sensitivity; Figure 4B).
Clinicopathological relevance of NHL discriminating low-
mass ions in urine
Neither of the two NHL-discriminating low-mass ions,
hypoxanthine and xanthine, was significantly correlated
with individual histologic types, cancer stage, extra-
nodal involvement, Eastern Cooperative Oncology
Group score (ECOG performance), international prog-
nostic index (low, low/intermediate vs. high/intermedi-
ate, high), bone marrow involvement (absent vs.
present), first response to chemotherapy (complete
response, partial response vs. stable disease, progressive
disease) or survival (data not shown).
Discussion
Previous efforts to find diagnostic factors for NHL have
yielded disappointing results compared with studies
reporting prognostic factors with clinicopathological
correlations [5,6]. Our previous study showed that the
urine level of IL-8 normalized to creatinine could be a
possible biomarker with the capacity to discriminate
NHL patients from normal controls; thus, we expected
that urine might be a valuable biological source for diag-
nostic markers for NHL [7].
In the present study, we sought to develop a new
diagnostic approach for NHL, using MALDI-MS analy-
sis to translate the information of low-mass ions (i.e., <
~1000 m/z) present in urine samples into a tool capable
of discriminating NHL patients from normal individuals.
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Figure 1 Selection of two low-mass ions with differential peak areas in urines from controls and NHL patients after establishing
MALDI-MS conditions for low-mass-ion profiling. A. The resolution of mass peaks acquired at variable focus mass. Linear resolution of low-
mass peaks was obtained at a focus mass of 500 m/z. B. The effect of laser intensity on overall mass spectrum acquisition. Laser intensity was
positively correlated with the area of low-mass peaks (< 1000 m/z). Because low-mass peaks with the highest intensity become saturated at a
laser intensity of 5500, the laser intensity for data acquisition was fixed at 5250. C. Typical pattern of mass spectra from urines from controls and
NHL patients. D. Box plot of total area of low-mass peaks (< 1000 m/z). The total area of low-mass peaks was obtained from four replicate
experiments (cases A to D) using urines from 12 controls (green) and 11 NHL patients (pink).
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Page 4 of 9Figure 2 Discriminating NHL patients from controls based on low-mass ions present in urine. A. Principal components analysis (PCA). The
first principle component (PC1) explains the greatest amount of variance, and PC2 represents the next largest amount. Left panel: Unsupervised
PCA showing that profiling of low-mass ions in urine may discriminate NHL patients. Right panel: Supervised PCA describing low-mass ions with
differential mass-peak intensities in urines from controls and NHL patients. B. Thirty low-mass ions selected by t-test analysis. C. Profile plot
focused on 137.08 m/z peaks. The profile plot demonstrates a higher peak intensity of the 137.08-m/z ion in urines from NHL patients compared
to that in controls in both training and validation groups. Lower panel describes overlapped mass spectra of four urine samples from NHL
patients and controls from blue box in profile plot.
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Page 5 of 9There are two motivations for our focus on this
low-mass range. The first is the existence of valuable
information in the low-mass range, analyzed by mass
spectrometry, that has not yet been systematically
exploited. Second, ions in the low-mass range provide
an enormous amount of information about biological
changes that originate from alterations in gene and pro-
tein expression. We hypothesized that a new non-inva-
sive cancer-screening protocol could be established if
low-mass-ion data were properly collected, statistically
translated, and analyzed by MALDI-MS.
Interestingly, a low-mass ion appeared at 137.08 m/z
that was significantly different in urine samples from
NHL patients and controls (Figure 2B &2C). Searching
the Human Metabolome Database (HMDB) yielded a
list of candidate metabolites corresponding to the
137.08-m/z ion (Table 2). An ESI-MS/MS analysis of
low-mass ions in urine identified 137.08 m/z as hypox-
anthine (Figure 3B and 3C). Consistent with this identi-
fication, the concentration of hypoxanthine in urine
compared favorably with the MALDI-MS profile of the
137.08-m/z ion (Figure 3C).
The Low-mass ion profiling is absolutely depends on
the accurate mass measuring technology. Recent mass
spectrometers employing either MALDI-, or ESI-based
technology provide very accurate mass information.
Using this advanced technology, we herein were able to
suggest a possible application of low-mass ion profiling
for cancer screening. However, a couple of problems are
still remained. First, software for low-mass ion profiling
is still incomplete. During the normalization process of
mass spectra obtained from each individual samples,
software sometimes collects the noise on the mass spec-
trum as a low-intensity peaks with discriminating
power. To prevent this nose picking, low-mass ions
ranked by software have to be checked again on the raw
mass spectra. Furthermore, the low-mass ions with low-
intensity, even they have a great discriminating power,
may not be proper for identification. This is the reason
why the low-mass ion with 137.08 m/z was selected for
identification since it showed highest intensity among
the low-mass ions ranked within 30
th (Figure 2B).
In patients with gastric cancer or colorectal cancer,
purine bases in plasma have been reported to increase
in association with a decreasei np u r i n eb a s ee x c r e t i o n
[8]. Whether hypoxanthine and xanthine levels are
altered in urine samples from gastrointestinal cancer
patients is still a matter of debate [8]. In plasma from
children with acute lymphoblastic leukemia or NHL,
hypoxanthine levels were reported to be higher than
those in healthy adult controls; these elevated plasma
hypoxanthine levels decreased after methotrexate infu-
sion [9]. However, a change in urine levels of hypox-
anthine has not yet been reported.
At present, we are unable to explain the underlying
mechanism for the change in hypoxanthine, but one
possibility may be found in alterations of purine meta-
bolism that occur during tumor development. Intracel-
lular concentrations of hypoxanthine and xanthine are
inversely related to adenylate energy changes and,
therefore, to the energy currency of cellular ATP [10].
Recently, a classical antifolate has been shown to pos-
sess cytotoxic activity against human prostatic cancer
cell lines that lacked hypoxanthine, whereas growth
was maintained in tumors with hypoxanthine [11]. We
reasoned that the level of hypoxanthine in NHL urines
might decrease due to consumption by tumor cells.
However, a recent study has shown that urinary
hypoxanthine is significantly increased when tumor
development in mesothelioma-transplanted nude mice
was maximized [12]. In addition, changes in the activ-
ity or expression of enzymes involved in hypoxanthine
or xanthine metabolism, which might affect hypox-
anthine and xanthine levels in NHL urines, cannot be
ruled out. For example, xanthine oxidoreductase, a key
enzyme in the degradation of DNA and RNA, is asso-
ciated with histological grade of differentiation and
extent of disease in colorectal cancer [13], as well as
the migratory activity of human breast cancer cells
[14,15].
Table 2 Metabolites with 137.07 ± 0.05 m/z in a positive-mode mass detection
HMDB ID Common Name Chemical
Formula
Adduct MW (Da)
[Matching HMDB MW]
MW Difference (Da)
[QueryMass - AdductMass]
Adduct
HMDB03152 N-Methylnicotinamide C7H8N2O 137.070938 [136.063660] 0.004333 M+H [1+]
HMDB00209 Benzeneacetic acid C8H8O2 137.059708 [136.052429] 0.006897 M+H [1+]
HMDB01326 Phenyl acetate C8H8O2 137.059708 [136.052429] 0.006897 M+H [1+]
HMDB11659 2-Methylerythritol C5H12O4 137.080841 [136.073563] 0.014236 M+H [1+]
HMDB01216 Tetrahydropteridine C6H8N4 137.082184 [136.074905] 0.015579 M+H [1+]
HMDB00157 Hypoxanthine C5H4N4O 137.045792 [136.038513] 0.020813 M+H [1+]
HMDB00613 Erythronic acid C4H8O5 137.044449 [136.037170] 0.022156 M+H [1+]
HMDB00943 Threonic acid C4H8O5 137.044449 [136.037170] 0.022156 M+H [1+]
M+H[1+] adducts only are listed.
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Page 6 of 9Figure 3 Identical ESI-MS/MS pattern obtained from 137.08 m/z ion in urine and hypoxanthine. A. Mass shift of the 137.08-m/z ion in
urine in LTQ-XL analysis. In a direct urine analysis without LC separation, the urine candidate 137.08-m/z ion and hypoxanthine (HX) were
monitored as 137.70 m/z. B. The ESI-MS/MS pattern of the 137.08-m/z ion in urine was identical to that of HX. C. Mass-peak area of the 137.08-
m/z ion and HX concentration were positively correlated; however, this relationship did not reach statistical significance.
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Page 7 of 9Figure 4 Significant decrease of hypoxanthine and xanthine in NHL urine. The levels of hypoxanthine (HX) (A) and its oxidative product,
xanthine (X) (B) were significantly lower in NHL urines (both P < 0.001). Area under the curve, sensitivity and specificity obtained from blind
validation of 221 urines samples (125 control, and 96 NHL) are shown.
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Page 8 of 9Conclusions
T h ep r e s e n ts t u d yr e p r e s e n t sag o o de x a m p l eo fl o w -
mass-ion profiling in the setting of disease-screening
using urine samples. This technique can be a powerful,
non-invasive diagnostic tool with high sensitivity and
specificity for NHL screening. Furthermore, hypox-
anthine identified in this study may be a useful single
urine marker for NHL screening. However, the bio-
chemical mechanism responsible for the decreased levels
of hypoxanthine and xanthine in urine samples from
NHL patients remains to be elucidated.
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